Kainos Medicine, Inc. (KOSDAQ:284620)

Kainos Medicine Statistics

Total Valuation

Kainos Medicine has a market cap or net worth of KRW 35.56 billion. The enterprise value is 37.38 billion.

Market Cap	35.56B
Enterprise Value	37.38B

Important Dates

The next estimated earnings date is Friday, November 14, 2025.

Earnings Date	Nov 14, 2025
Ex-Dividend Date	n/a

Share Statistics

Kainos Medicine has 32.71 million shares outstanding. The number of shares has increased by 4.46% in one year.

Current Share Class	32.71M
Shares Outstanding	32.71M
Shares Change (YoY)	+4.46%
Shares Change (QoQ)	+15.28%
Owned by Insiders (%)	22.73%
Owned by Institutions (%)	n/a
Float	22.95M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	43.35
PB Ratio	3.72
P/TBV Ratio	12.35
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-3.49
EV / Sales	45.56
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.33

Financial Position

The company has a current ratio of 3.54, with a Debt / Equity ratio of 0.03.

Current Ratio	3.54
Quick Ratio	2.93
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	-0.04
Interest Coverage	-225.05

Financial Efficiency

Return on equity (ROE) is -84.30% and return on invested capital (ROIC) is -46.49%.

Return on Equity (ROE)	-84.30%
Return on Assets (ROA)	-41.79%
Return on Invested Capital (ROIC)	-46.49%
Return on Capital Employed (ROCE)	-102.17%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.06
Inventory Turnover	n/a

Taxes

In the past 12 months, Kainos Medicine has paid 1.15 million in taxes.

Income Tax	1.15M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -73.03% in the last 52 weeks. The beta is 1.30, so Kainos Medicine's price volatility has been higher than the market average.

Beta (5Y)	1.30
52-Week Price Change	-73.03%
50-Day Moving Average	1,104.96
200-Day Moving Average	1,939.78
Relative Strength Index (RSI)	50.94
Average Volume (20 Days)	481,084

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Kainos Medicine had revenue of KRW 820.31 million and -10.72 billion in losses. Loss per share was -367.85.

Revenue	820.31M
Gross Profit	566.10M
Operating Income	-9.81B
Pretax Income	-10.72B
Net Income	-10.72B
EBITDA	-8.93B
EBIT	-9.81B
Loss Per Share	-367.85

Balance Sheet

The company has 4.70 billion in cash and 302.96 million in debt, giving a net cash position of 4.40 billion or 134.57 per share.

Cash & Cash Equivalents	4.70B
Total Debt	302.96M
Net Cash	4.40B
Net Cash Per Share	134.57
Equity (Book Value)	9.57B
Book Value Per Share	102.39
Working Capital	5.12B

Cash Flow

In the last 12 months, operating cash flow was -8.63 billion and capital expenditures -3.40 million, giving a free cash flow of -8.63 billion.

Operating Cash Flow	-8.63B
Capital Expenditures	-3.40M
Free Cash Flow	-8.63B
FCF Per Share	-263.85

Margins

Gross Margin	69.01%
Operating Margin	-1,196.13%
Pretax Margin	-1,306.80%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Kainos Medicine does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.46%
Shareholder Yield	n/a
Earnings Yield	-30.15%
FCF Yield	-24.27%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on June 24, 2022. It was a reverse split with a ratio of 0.2.

Last Split Date	Jun 24, 2022
Split Type	Reverse
Split Ratio	0.2

Scores

Kainos Medicine has an Altman Z-Score of 5 and a Piotroski F-Score of 2.

Altman Z-Score	5
Piotroski F-Score	2